Renalase peptides reduce pancreatitis severity in mice-Reference-Cited by-同舟云学术

Renalase peptides reduce pancreatitis severity in mice

Published:2024-09-01 Issue:3 Volume:327 Page:G466-G480
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Kolodecik Thomas R.¹²,Guo Xiaoyu³⁴,Shugrue Christine A.¹²,Guo Xiaojia¹²,Desir Gary V.¹²,Wen Li³⁴,Gorelick Fred¹²^ORCID

Affiliation:

1. Veterans Affairs Health Care System, Yale University, New Haven, Connecticut, United States

2. Yale School of Medicine, Yale University, New Haven, Connecticut, United States

3. State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, People’s Republic of China

4. Center for Biomarker Discovery and Validation, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, People’s Republic of China

Abstract

Renalase is a secretory protein. The prosurvival and anti-inflammatory effects of the whole molecule are contained in a 20 aa renalase site (RP220). Systemic treatment with peptides containing this renalase site reduced the severity of post-endoscopic retrograde cholangiopancreatography (ERCP) and severe cerulein pancreatitis in mouse models.

Funder

National High Level Hospital Clinical Research Funding

CAMS Innovation Fund for Medical Science

DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs

MOST | National Natural Science Foundation of China

Veterans Administration Medical Center, Yale School of Medicine

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00143.2024

Reference29 articles.

1. Acute Pancreatitis

2. Acute pancreatitis

3. A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

4. The Orai Ca 2+ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis